About this trial
In people diagnosed with lymphoma receiving immunochemotherapy treatment, a combined exercise intervention, as opposed to the general recommendations, will achieve: 1.Improve cardiorespiratory fitness, strength, psychological well-being and quality of life. //2.Reduce fatigue//3.Reduce frailty
There is an association between some biological biomarkers with physical capacity and frailty.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age: ≥18 years old.
Diagnosis of lymphoma with histological confirmation and requirement of systemic treatment including chemotherapy.
Time available (80 minutes, two days a week for 20 weeks) to carry out physical exercise sessions.
Have a mobile phone to be able to contact the person and download the physical activity level app.
Disqualifiers
Have a contraindication to moderate-high intensity exercise.
Other significant medical disorders: including psychiatric illnesses chronic or recurrent; intellectual disability, musculoskeletal problems, cardiac or pulmonary disorders that interfere with physical exercise; other malignant tumors in the last five years, with the exception of therapeutically controlled skin cancer; any other illness that may be seen affected or aggravated by physical exercise.
Have plans to be outside city more than two weeks.
People who are already physically active (that comply with the recommendations of WHO: > 150 minutes of exercise moderate/weekly, plus training force two days/week).
Trial design
Parallel
Treatments tested in this trial
Exercise
Other interventionThe lymphoma unit of the Donostia University Hospital (HUD) is part of the Onkofrail project that analyzes the impact of a physical activity in older cancer patients. The Onkofrail study has included everything type of solid tumors and very diverse treatments, which is a limitation methodology that could condition the analysis of the results. Therefore, the need of proposing a new PE project in a homogeneous population such as that of people with lymphoma, the most prevalent hemopathy in our environment, which has a great survival, but present important adverse effects secondary to treatment systemic.
Treatment groups
Trial outcomes
Primary outcomes
Cardiorespiratory fitness (CRF)
Measured by peak oxygen uptake (VO2peak) before starting chemotherapy treatment and after 20 weeks of intervention, using the cardiorespiratory exercise test.
Secondary outcomes
Sociodemographic, etiological and clinical health variables (A)
Recruitment Center (Donostia University Hospital, Galdakao University Hospital , Alava University Hospital)
Sociodemographic, etiological and clinical health variables (B)
Birthdate.
Sociodemographic, etiological and clinical health variables (C)
Biological sex (man, woman, I prefer not to answer)
Sociodemographic, etiological and clinical health variables (D)
Gender (man, woman, non-binary or I prefer not to answer)
Sponsors and contacts
Click on the lead sponsor to view all of their trials.